Considering that upregulated NF-kB signaling pathway plays a critical role in IBD progression, Han et al. [114] hypothesized that different NF-kB activation levels influence CD’s clinical manifestations during the patient’s disease course. The gene discussed is NFKB1; the disease is inflammatory bowel disease.